|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Troponin T, High Sensitivity (hs-TnT)
Test Code38685
CPT Codes
84484
Preferred Specimen
1 mL plasma collected in a lithium heparin (green-top) tube
Minimum Volume
0.5 mL
Instructions
Collect using standard venipuncture techniques in lithium heparin tube only
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: Unacceptable
Refrigerated: 7 days
Frozen: 1 year
Refrigerated: 7 days
Frozen: 1 year
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis • Grossly lipemic • Grossly icteric • Serum
Methodology
Electrochemuluminescence Immunoassay
Setup Schedule
Set up: Tues, Thurs, Sat; Report available: 1-2 days
Reference Range
| Male | <23 ng/L |
| Female | <15 ng/L |
Clinical Significance
This test measures cardiac troponin T (cTnT) level, an independent prognostic marker that aids in the diagnosis of myocardial infarction (MI) in an acute setting.
Studies have also suggested an increased relative risk of all-cause mortality and other disease processes such as stroke and respiratory disease.[1]
Cardiac troponins are normally involved in heart muscle contraction, but when heart muscle cells die, they release proteins into the blood. In appropriate symptomatic patients, these proteins are biomarkers for cardiovascular diseases (CVDs) related to myocardial ischemia or infarction (ie, acute coronary syndrome [ACS]). High levels of cardiac troponin in the blood (ie, above the 99th percentile upper reference limit [URL]) identify patients with likely myocardial ischemia who would benefit from expedited cardiac care.[2-4] For this reason, tests for either cardiac troponin T (cTnT) or cardiac troponin I (cTnI) are routinely used to evaluate symptomatic patients with ACS for myocardial injury and myocardial infarction.[4,5]
In asymptomatic patients, high-sensitivity (hs) cTnT tests have utility for risk assessment. Studies have shown that high to even moderate cTnT levels, which are less accurately detected by older-generation troponin tests,[6] are associated with risk of incident CVD [7-10] and death.[7-9, 11,12] This association is independent of conventional CVD risk factors, and risk increases with cTnT concentration. [7-13] Additionally, increasing cTnT across multiple years is associated with increased risk, while decreasing cTnT is associated with decreased risk.[13,14] Elevated cTnT is also predictive of cardiovascular events and death among patients with CVD (ie, chronic heart failure,[15] coronary heart disease,[16] ACS [17]).
This test is suitable for individuals who may benefit from refinement of CVD risk assessment and those with symptoms associated with suspected ACS.
Caution is recommended when testing older adults, in whom chronic elevations are common and may not be actionable.[18]
The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.
References
1. Oluleye OW, et al. Ann Epidemiol. 2013;23(2):66-73.
2. Daubert MA, et al. Vasc Health Risk Manag. 2010; 6:691-699.
3. Bhatt DL, et al. JAMA. 2022;327(7):662-675.
4. Amsterdam EA, et al. Circulation. 2014;130(25):e344-e426.
5. Thygesen K, et al. Eur Heart J. 2019;40(3):237-269.
6. Twerenbold R, et al. J Am Coll Cardiol. 2017;70(8): 996-1012.
7. Willeit P, et al. J Am Coll Cardiol. 2017;70(5):558-568.
8. de Lemos JA, et al. JAMA. 2010;304(22):2503-2512.
9. Saunders JT, et al. Circulation. 2011;123(13):1367-1376.
10. Seliger SL, et al. Circulation. 2017;135(16):1494-1505.
11. van der Linden N, et al. Medicine (Baltimore). 2016/12/30 ed. 2016:chap 52.
12. Oluleye OW, et al. Ann Epidemiol. 2013;23(2):66-73.
13. deFilippi CR, et al. JAMA. 2010;304(22):2494-2502.
14. McEvoy JW, et al. JAMA Cardiol. 2016;1(5):519-528.
15. Aimo A, et al. Circulation. 2018;137(3):286-297.
16. Beatty AL, et al. JAMA Intern Med. 2013;173(9):763-769.
17. Weber M, et al. Am Heart J. 2011;162(1):81-88.
18. Damluji A, et al. Circulation. 2023;147(3):e32-e62.
Studies have also suggested an increased relative risk of all-cause mortality and other disease processes such as stroke and respiratory disease.[1]
Cardiac troponins are normally involved in heart muscle contraction, but when heart muscle cells die, they release proteins into the blood. In appropriate symptomatic patients, these proteins are biomarkers for cardiovascular diseases (CVDs) related to myocardial ischemia or infarction (ie, acute coronary syndrome [ACS]). High levels of cardiac troponin in the blood (ie, above the 99th percentile upper reference limit [URL]) identify patients with likely myocardial ischemia who would benefit from expedited cardiac care.[2-4] For this reason, tests for either cardiac troponin T (cTnT) or cardiac troponin I (cTnI) are routinely used to evaluate symptomatic patients with ACS for myocardial injury and myocardial infarction.[4,5]
In asymptomatic patients, high-sensitivity (hs) cTnT tests have utility for risk assessment. Studies have shown that high to even moderate cTnT levels, which are less accurately detected by older-generation troponin tests,[6] are associated with risk of incident CVD [7-10] and death.[7-9, 11,12] This association is independent of conventional CVD risk factors, and risk increases with cTnT concentration. [7-13] Additionally, increasing cTnT across multiple years is associated with increased risk, while decreasing cTnT is associated with decreased risk.[13,14] Elevated cTnT is also predictive of cardiovascular events and death among patients with CVD (ie, chronic heart failure,[15] coronary heart disease,[16] ACS [17]).
This test is suitable for individuals who may benefit from refinement of CVD risk assessment and those with symptoms associated with suspected ACS.
Caution is recommended when testing older adults, in whom chronic elevations are common and may not be actionable.[18]
The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.
References
1. Oluleye OW, et al. Ann Epidemiol. 2013;23(2):66-73.
2. Daubert MA, et al. Vasc Health Risk Manag. 2010; 6:691-699.
3. Bhatt DL, et al. JAMA. 2022;327(7):662-675.
4. Amsterdam EA, et al. Circulation. 2014;130(25):e344-e426.
5. Thygesen K, et al. Eur Heart J. 2019;40(3):237-269.
6. Twerenbold R, et al. J Am Coll Cardiol. 2017;70(8): 996-1012.
7. Willeit P, et al. J Am Coll Cardiol. 2017;70(5):558-568.
8. de Lemos JA, et al. JAMA. 2010;304(22):2503-2512.
9. Saunders JT, et al. Circulation. 2011;123(13):1367-1376.
10. Seliger SL, et al. Circulation. 2017;135(16):1494-1505.
11. van der Linden N, et al. Medicine (Baltimore). 2016/12/30 ed. 2016:chap 52.
12. Oluleye OW, et al. Ann Epidemiol. 2013;23(2):66-73.
13. deFilippi CR, et al. JAMA. 2010;304(22):2494-2502.
14. McEvoy JW, et al. JAMA Cardiol. 2016;1(5):519-528.
15. Aimo A, et al. Circulation. 2018;137(3):286-297.
16. Beatty AL, et al. JAMA Intern Med. 2013;173(9):763-769.
17. Weber M, et al. Am Heart J. 2011;162(1):81-88.
18. Damluji A, et al. Circulation. 2023;147(3):e32-e62.

